NCT01894061View on ClinicalTrials.gov

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 18, 2013

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
BIOLOGICAL

Bevacizumab

Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.

DEVICE

NovoTTF-l00A

NovoTTF-100A will be worn continuously.

OTHER

Quality of Life Assessment

Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire

Trial Locations (3)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

45220

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Case Comprehensive Cancer Center

OTHER

NCT01894061 - NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter